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Background: Major depressive disorder (MDD) is a long-lasting disorder with frequent relapses that have significant
effects on the patient’s family. Family psychoeducation is recognized as part of the optimal treatment for patients
with psychotic disorder. A previous randomized controlled trial has found that family psychoeducation is effective
in enhancing the treatment of MDD. Although MDD can easily become a chronic illness, there has been no
intervention study on the families of patients with chronic depression. In the present study, we design a randomized
controlled trial to examine the effectiveness of family psychoeducation in improving the mental health of relatives
of patients with MDD lasting more than one year.
Methods/Design: Participants are patients with MDD lasting more than one year and their relatives. Individually
randomized, parallel-group trial design will be employed. Participants will be allocated to one of two treatment
conditions: relatives will receive (a) family psychoeducation (four, two-hour biweekly multifamily psychoeducation
sessions) plus treatment-as-usual for the patient (consultation by physicians), or (b) counseling for the family
(one counseling session from a nurse) plus treatment-as-usual for the patient. The primary outcome measure will
be relatives’ mental health as measured by K6 that was developed to screen for DSM-IV depressive and anxiety
disorder. Additionally, the severity of depressive symptoms in patients measured by the Beck Depression
Inventory–II (BDI-II) scale will be assessed. Data from the intention-to-treat sample will be analyzed 16 weeks after
randomization.
Discussion: This is the first study to evaluate the effectiveness of family psychoeducation for relatives of patients
with MDD lasting more than one year. If this type of intervention is effective, it could be a new method of
rehabilitation for patients with MDD lasting more than one year.
Trial registration: Clinical Trials.gov NCT01734291 (registration date: 18 October 2012).
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Major depressive disorder (MDD) is a common disorder,
widely distributed throughout the population, and usu-
ally associated with substantial symptoms and role im-
pairment. The prevalence of cases of lifetime MDD was
16.2% in the United States and 12.8% in Europe [1,2].
The mean duration of a depressive episode was 16 weeks
and 59.3% of patients with MDD lasting just one year
had severe or very severe role impairment [1]. Moreover,
MDD is a long-lasting illness with significant effects on
the patient’s family, social life, and work life [3,4]. Treat-
ment failure results in a low recovery rate and frequent
relapses [5]. According to studies on the naturalistic
course of MDD, a prospective study in Japan showed that
10 to 20% of patients entering treatment remain chroni-
cally depressed without recovery for one or even two
years [6]. Once recovered, the cumulative probability of
remaining well without subthreshold symptoms was 57%
at one year, 47% at two years, and 35% at five years [7].
MDD can also cause severe suffering for family mem-
bers of the patient in multiple areas including a higher
level of divorce [8] and severe financial strain [9].
Fadden et al. [10] reported that the burden on the rela-
tives of patients with MDD included restrictions in
social and leisure activities, a fall in family income, and a
considerable strain on the marital relationship. Relatives
of patients with depression found some of the behaviors
of the patients to be difficult to bear, and the relatives
had negative consequences such as grief, withdrawal,
and worrying, which commonly caused problems. How-
ever, few relatives know how to deal with the difficult
behavior of patients [10]. Moreover, sleep disturbance,
odd ideas and/or behavior, and appetite loss in MDD pa-
tients were not seen by any relatives as being under the
patient’s control, whereas nagging, grumbling, obsession-
ality, and worrying were seen by a varying proportion of
relatives as personality attributes [10]. Therefore, the
relatives felt dissatisfaction in that the patient could
control those behaviors [10]. Jacob et al. [11] reported
disruptions in the lives of close family members because
of their own worrying and also because of the patient’s
lack of interest in things and feelings of worthlessness.
Taken together, these findings suggest that living with a
patient with MDD is a source of strain and emotional
distress for relatives.
Among relatives of patients with MDD, the patient’s
behavior and mood disturbance and relative’s emotional
distress were associated with the relatives’ mental health
[12-14]. The difficultness of maintaining functioning
family relationships (for example the patient may have
marital problems, poorer communication, and no problem-
solving skills) was associated with poorer long-term out-
come for the depression [15,16]. Rounsaville et al. [17]
reported that a reduction in the number of maritaldisputes was associated with improved depressive symp-
toms and social functioning after eight months of indi-
vidual psychotherapy in depressed female outpatients.
Several studies reported that the quality of family func-
tioning was associated with the relapse rate. The family’s
expressed emotion (EE) is a good predictor of whether a
patient relapses; Hooley et al. [18] reported that 59% of
patients whose spouses had high levels of EE relapsed,
although no patients living with low-EE spouses did so
over a nine-month follow-up period. Although Hayhurst
et al. [19] reported that there was no clear association be-
tween the EE of a spouse and the recurrence of depression
in the patient, five studies reported that a high EE
predicted a high relapse rate [18,20-23].
These studies suggest the need for a more family-
oriented approach in the treatment of MDD. However, a
review conducted by Henken et al. [24] reported that
family therapy such as behavioral intervention including
psychoeducation, psychodynamic intervention, and sys-
temic intervention for the families of patients with de-
pression, seems to be more effective than no treatment
or being placed on a waiting list. However it remains
unclear how effective this intervention is in comparison
with other interventions such as group intervention,
individual cognitive intervention, and behavioral inter-
vention. In spite of the lack of high-quality evidence in
this field, family therapy is already a widely-used inter-
vention for the treatment of depression [24].
Family psychoeducation is recognized as part of the op-
timal treatment for patients with a psychotic disorder
[25,26]. This intervention has been shown to reduce the
rates of relapse and hospitalization among individuals with
psychotic disorders and is recognized as an evidenced-
based treatment for psychotic disorders [27]. Two random-
ized controlled trials have found that family psychoeduca-
tion is effective in enhancing the course of MDD [28,29]. In
a study of adolescents with MDD, patients in the group
who received family psychoeducation showed greater im-
provements in social functioning and adolescent-parent re-
lationship than the control group [28]. Among patients
with MDD in partial or full remission, patients who were
treated with the family psychoeducation had a significantly
lower relapse rate than patients who were in the control
group [29]. However, neither of these two trials assessed
relatives’ mental health as the primary outcome. Addition-
ally, although MDD can easily become chronic, there has
been no intervention study for the families of patients with
MDD lasting more than one year.
Aims
In the present study, we perform a randomized controlled
trial to examine the effectiveness of family psychoeducation
in improving the mental health of the relatives of patients
with MDD lasting more than one year. The hypothesis is
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counseling session from a nurse, relatives receiving family
psychoeducation will show a greater improvement in men-




This randomized controlled trial will be conducted in pa-
tients with MDD who will be allocated to one of two
arms: family psychoeducation in addition to treatment-as-
usual for the patients, and treatment-as-usual. Treatment-
as-usual consists of consultation administered by a phys-
ician and counseling by a nurse. The primary endpoint is
improvement of the mental health of patients’ relatives as
measured by K6 scale at 16 weeks (Figure 1). We defined
mental health as the state of health of the mind and that
when the mental health of relatives was in an unhealthy
state, the person suffered from mental disorder such as
depressive and anxiety disorder.
Participants: inclusion and exclusion criteria
The target population will be patients with MDD lasting
more than one year and their relatives (fathers, mothers,
husbands, wives, daughters, and sons of patients). Inclu-
sion criteria will be: the patient meets the criteria for
MDD according to the DSM-IV (Diagnostic and Statis-
tical Manual of Mental Disorder 4th edn) based on the
consensus rating by psychiatrists (who have more than
five years’ experience as a physician and more than two
years’ experience as a psychiatrist) in charge without
using a structured interview; the patient receives anti-
depressant therapy; the patient had the first episode of
MDD more than one year prior; the patient currently
fulfills the diagnostic threshold for major depressive epi-
sode or partial remission; the patient and their family
member(s) are aged between 18 and 85 years; the patient
lives with his or her family at the time of participating in
this study and is expected to live with his or her family
during the investigation period. Exclusion criteria will
be: patients who undergo electroconvulsive therapy
(ECT) during the investigation period and patients who
are at serious suicidal risk.
Procedure
This study was approved by the Ethics Review Committee
of Nagoya City University Graduate School of Medicine
(reference number 679). All participants will provide writ-
ten informed consent after the purpose and procedures of
the study are explained. This study is registered at Clini-
calTrials.gov under number NCT01734291. We will pro-
vide eligible patients with an ID number and then ask
patients and their relatives to provide informed consent
and complete a baseline assessment (Assessment I). Afterproviding informed consent and completing the baseline
assessment, participants will be randomized. Assessment
will occur at baseline, before randomization, and at 8, 16,
and 32.
Randomization
Participants will be randomly allocated to one of the two
groups with equal probability. This random assignment
will be made in a 1:1 ratio. An independent statistician
will generate the random allocation sequences by a com-
puter using minimization [30], and stratify the relatives
according to the severity of mental state (K6 score of 5
or more, or less than 5). Allocation sequences will be
kept centrally and the allocation will be provided by fac-
simile to us. The randomization schedule is not available
to anyone except the statistician.
Treatment
Multifamily psychoeducation
The family intervention program, which we call ‘multi-
family psychoeducation’, is based on the McFarlane Model
[31], the Evidence-Based Practices Toolkit for Family
Psycho-Education [32], and the standard model of the
Japanese Network of Psychoeducation and Family Support
Program (JNPF) [33]. The multifamily psychoeducational
program will consist of four sessions. Each of the four
multifamily psychoeducational program groups will con-
sist of the relatives of approximately four patients. The
staff will consist of one or two psychiatrists, one or two
nurses, one pharmacologist, and one social worker. The
teaching materials for the relatives of the patients are a
videotape produced by the Department of Neuropsych-
iatry, Kochi Medical School [34], including the videotaped
interview of the experience of a patient with MDD, an ex-
planation of the cause of MDD using computer graphics
images of synapses and neurotransmitters, and a booklet
developed by our department. At the first session we will
give the participants information on the causes and symp-
toms of major depression, at the second session we will
provide information on drug treatment, at the third ses-
sion we will provide information on community resources,
and at the fourth session we will provide guidelines for
families caring for patients. After the lecture in each
session, we will provide supportive group therapy focusing
on problem-solving skills for approximately 90 minutes.
In the group therapy sessions, the participants will be en-
couraged to give a narrative of their subjective experience
in taking care of the MDD patient. Each session will last
approximately two hours. The groups will meet once
every two weeks over the course of six weeks.
Control group
The patients in both the intervention and control groups
will receive standard outpatient or inpatient treatment
Figure 1 Participant flow diagram. K6, J-ZBI_8; The Japanese version of the Zarit Burden Interview short version, FAS; The Japanese version of
the Family Attitude Scale, BDI-II; Beck Depression Inventory-II, SF-36; The Medical Outcomes Study 36-item short form health survey (SF-36) version
2, FAD; The Japanese version of the Family Assessment Device.
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of evaluation of psychiatric symptoms, antidepressant
pharmacotherapy, and supportive psychotherapy on a bi-
weekly or-four-weekly basis. Inpatient treatment consists
of sufficient rest for the patient, evaluation of psychiatric
symptoms, antidepressant pharmacotherapy, and suppor-
tive psychotherapy. All of the participants will receive
some case management. Family treatment in the control
group consists of one counseling session administered by
a nurse. This counseling consists of listening to any issues
or problems and providing any information that is ask for.
The information requested is usually regarding their com-
munication, relapses, and how to take their drugs. We se-
lected this counseling treatment as the control group’streatment, because active listening to relatives’ suffering
and giving information on recuperation from nurses are
within the scope of treatment-as-usual. The one session of
counseling by a nurse will last 45 minutes.
Therapist training, supervision and fidelity control
Authors FK, NS, and MS were each trained and certified
as a family psychoeducation instructor by the JNPF [33].
All staff except one pharmacologist had participated in
intensive training which consisted of more than eleven
hours using the treatment manual of the JNPF [33]. In
order to ensure the fidelity of each session, all sessions
will be audiotaped and 25% of each condition will be
randomly selected, evaluated, and commented about for
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searcher. The counseling session in treatment-as-usual
administered by a nurse will also be audiotaped and
20% of each condition will be randomly selected and
evaluated by an independent researcher. The raters will
each be trained and certified as a family psychoeduca-
tion instructor by the JNPF.Outcome measure
Primary outcome measure of family members - K6
The K6 questionnaire is a six-item self-report question-
naire that was developed to screen for any DSM-IV de-
pressive and anxiety disorders within 30 days prior to its
administration and which can also be used to quantify
nonspecific psychological distress in general [35]. The
participants of this study will not be individuals with a
mental disease but will be among the general population,
and our previous study showed that the K6 was excellent
for measuring changes in the mental health of relatives
of MDD patients [36]. K6 has a high screening perform-
ance for mood and anxiety disorder, equal to that of the
Center for Epidemiologic Studies-Depression Scale
(CES-D) [37]. Each item in the K6 questionnaire is rated
between 0 = ‘none of the time’ and 4 = ‘all of the time’,
and the total score therefore ranges from 0 to 24. Two
independent validation studies found the K6 to have an
area under the receiver operating characteristic curve
between 0.86 and 0.89 in predicting the diagnosis of
mental illness based on comprehensive diagnostic inter-
views [35,38]. The Japanese version of the K6 question-
naire showed excellent efficacy in screening for anxiety
and mood disorders in the Japanese general population,
with an area under the receiver operating characteristic
curve of 0.94 [39]. The Japanese version of the K10
questionnaire also showed excellent efficacy in screening
for anxiety and mood disorders in the Japanese general
population, with an area under the receiver operating
characteristic curve of 0.94 [39]. In this study, we will
use the K6 as it has fewer items than the K10.Secondary outcomes of family members
The Japanese version of the Zarit Burden Interview
short version (J-ZBI_8) The Zarit Burden Interview is
widely used to assess caregiver burden [40]. The
Japanese version of the Zarit Burden Interview (J-ZBI)
was developed by Arai et al., and the eight-item short
version of the J-ZBI (J-ZBI_8) was also developed by
Arai et al. [41-43]. The items in the J-ZBI_8 are rated on
a five-point Likert scale (0 = never to 4 = very often) and
the scores on the J-ZBI_8 range from 0 to 32. Cron-
bach’s α of the J-ZBI_8 was 0.89, and the Pearson’s
correlation coefficient between scores on the J-ZBI and
J-ZBI_8 was 0.93 [41].The Japanese version of the Family Attitude Scale
(FAS) The FAS, developed by Kavanagh et al. [44], is a
30-item self-report instrument and measures families’
EE. The scores for each item are added to give a total
score that ranges from 0 to 120, with higher scores in-
dicating higher levels of burden or criticism [44]. A
higher FAS rating was significantly correlated with
higher levels of criticism (r = 0.44), hostility (r = 0.41),
and emotional overinvolvement (EOI) (r = 0.27) in the
Camberwell Family Interview (CFI) [45]. The Japanese
version of the FAS, developed by Fujita et al. [46],
showed excellent validity. The relative sensitivity and
specificity of EE assessment with the FAS compared
with the criticism component of the CFI were 100% and
88.5%, respectively [46].
Beck Depression Inventory-II (BDI-II) BDI-II is a 21-
item self-report instrument to assess the existence and
severity of symptoms of depression [47]. It has good psy-
chometric properties and acceptability. Each item is
rated on a four-point scale ranging from 0 to 3. Studies
consistently support the BDI-II as a reliable, internally
consistent, and valid scale for assessing depression in
psychiatric outpatients and the general population, and
in primary care settings [47-49]. The reliability and
validity of the Japanese version have been found to be
excellent [50].
Secondary outcomes in patients
Beck depression inventory-II (BDI-II) We also se-
lected BDI-II as an outcome measure to evaluate the
severity of patients’ depressive symptoms.
The Medical Outcomes Study 36-item short form
health survey (SF-36) version 2 The SF-36 is a self-
report questionnaire to assess general quality of life. It
contains 36 items that constitute eight measures of
physical functioning (PF), role physical (RP), bodily pain
(BP), social functioning (SF), general health perceptions
(GH), vitality (VT), and mental health (MH). It also pro-
vides two summary measures, the physical component
summary (PCS) and the mental component summary
(MCS). The PCS is associated with PF, RP, BP, GH, and
VT. The MCS is associated with MH, RE, SF, VT, and
GH. The score of each measure ranges from 0 to 100,
and the higher the score, the higher the quality of life.
The Japanese version has shown good validity in the
general population of Japan [51,52].
The Japanese version of the Family Assessment
Device (FAD): J-FAD The FAD is a 60-item self-report
questionnaire developed by Epstein et al. [53] to assess
the six dimensions of the McMaster Model of Family
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tioning. The FAD consists of seven subscales: problem
solving, communication, roles, affective responsiveness,
affective involvement, behavior control, and general
functioning. The Japanese version of the FAD was devel-
oped by Saeki et al. and has shown good validity [54].
Sample size and statistical power
Sample size was based on a power analysis conducted
for the K6 score. Effect sizes were estimated from our
previous pilot study [36] (the mean change in the K6
scores pretreatment to post-treatment was 4.9 in 32 rela-
tives of patients with MDD). The change in the K6
scores pretreatment to post-treatment (16 weeks after
the randomization) was 4.5 ± 2.5 (mean ± SD) in the
family psychoeducation group and 2 ± 2.5 in the control
group. With a power of 0.9 to detect a significant differ-
ence at P = 0.05 (two-sided), it was calculated that 23 pa-
tients would be required for each arm. Thus, allowing
for a 20% dropout rate, 30 participants would need to be
recruited per group.
Statistical analysis
Statistical analyses will be performed using SPSS 19 J for
Windows. Descriptive data analysis will be conducted by
calculating mean scores and standard deviation. All ana-
lyses will be based on the intent-to-treat model. We will
use analysis of covariance at 16 weeks if there is no
missing data at that time. If missing data is observed, we
will use the maximum likelihood mixed model which ac-
counts for missing data, provided that the data are miss-
ing at random, conditional on the covariates and the
baseline values of the outcome. P <0.05 will be set to test
the null hypothesis.
Discussion
One randomized controlled trial found that family psy-
choeducation is effective in enhancing the course of
MDD [29]. MDD can easily become a chronic condition,
therefore, it is reasonable to assume that relatives of
these patients with MDD experience a heavy psycho-
social burden and show increased rates of depression
and anxiety [55,56]. However, there has been no inter-
vention study on the mental health of families of
patients with chronic depression. With such a back-
ground, this will be the world’s first study on family
psychoeducation in families of patients with MDD.
Moreover, the results will provide useful suggestions for
the comprehensive treatment of chronic depression.
This study has four major strengths. First, since a var-
iety of workers such as physicians, nurses, pharmacolo-
gists, and psychiatric social workers participate in this
family psychoeducational program, it is possible to as-
sess the family from various points of view. Physiciansare specialists of psychiatric treatment (especially pharma-
cotherapy); nurses are experts in providing guidance on
everyday life to patients and their relatives; the pharma-
cologist is an expert in the effects of medicine; and the
psychiatric social worker is knowledgeable about com-
munity resources. Thus, information is provided on a
wide range of topics from disease to treatment to com-
munication, and each expert is in charge of providing
information.
Second, the method of family psychoeducation employed
in this study is group therapy that improved the McFarlane
model according to the Japanese Network of Psychoeduca-
tion and Family Support Program and focuses more on the
strength of the family. With regard to the structure of the
multifamily group sessions, common steps in the problem-
solving process shared by the standard model of the
Japanese Network of Psychoeducation and Family Sup-
port Program and the McFarlane Model are: (1) socializ-
ing with other families, (2) defining the problem or goal,
(3) listing all possible solutions suggested by the group
members, and (4) the family member who presented the
problem chooses the solution that best fits the situation.
However, the standard model of the Japanese Network of
Psychoeducation and Family Support Program differs
from the McFarlane Model with regard to several points.
In the standard model of the Japanese Network of Psy-
choeducation and Family Support Program, the advan-
tages and disadvantages of each solution are not discussed
in detail and an action plan to carry out the solution is not
formed. According to the model, it is easier for all mem-
bers in the group to talk about and share their experiences
at each session and give advice to each other instead of fo-
cusing on the solution of a problem of only one member
in the group.
Third, the primary outcome of the study is the mental
health of the families, but the outcome of the patients is
also evaluated. In addition, not only the family but also
the patient is evaluated from a variety of aspects, includ-
ing family function and depressive symptoms. Fourth,
since the sample size was calculated in this study based
on the pilot study we had previously carried out [54], it
is possible to accurately estimate the required number
of cases.
This study has some limitations. First, the diagnosis of
MDD will not be made by a structured clinical interview
and comorbidities such as anxiety disorder are included.
However, it is not common to have a structured inter-
view for diagnosis in daily clinical practice and it is
known that MDD has a number of comorbidities. Sec-
ond, an objective evaluation tool such as the Hamilton
Depression Rating Scale will not be used, but the self-
report inventory will be used for evaluation of patients’
symptoms. Third, families with low levels of stress (K6
scores of four points or less) will be included among the
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not be excluded from receiving care just because they have
low levels of stress according to the questionnaire for the
family. Finally, although an attention-placebo arm must be
employed originally, we aim to conduct the study to
examine the effectiveness of family psychoeducation for
improvement of the mental health of relatives of patients
with MDD, including eight-hour contact with medical
professionals, but not to examine the efficacy of family
psychoeducation for MDD itself. Taken together, it would
be reasonable to say that this is an effectiveness study
under conditions more resembling an actual clinical set-
ting and the results would be widely applicable to clinical
practice immediately. Rehabilitation elements are impor-
tant in recovery from chronic disease, but no comprehen-
sive rehabilitation program for chronic MDD has been
sufficiently developed. If the efficacy is confirmed in this
study, it will be one of the useful rehabilitation programs
for chronic MDD.
Trial status
The trial is currently in the recruitment phase. The first
group was randomized on 12 October 2012.
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